Endocrine Abstracts

Background and aims: There is evidence that new anti-diabetic drugs may limit liver disease progression, reduce liver fat and normalize serum aminotranferase levels in patients with NAFLD. We compared the effectiveness of new drug classes on liver fat in T2DM patients by means of surrogate markers.Materials and methods: In an observational retrospective study we analysed the 12-month time-courses of clinical and anthropometric data of T2DM cases treated ...

We retrospectively studied the effect on BMI and metabolic control (HbA1c within therapeutic targets) of structured lifestyle intervention associated with glucagon-like-1 receptor agonists (GLP-1RA) compared to GLP-1RA alone in patients with Type 2 diabetes (T2DM).Materials and method: The anthropometric and clinical data of 525 T2DM patients who started therapy with GLP-1RA were collected in a comprehensive database with follow-up of 24 months. Accordin...